ERBB2 and breast cancer: For example, the NSABP B-31/-N9831 study established that AC-TH (doxorubicin combined with cyclophosphamide sequential paclitaxel drugs combined with trastuzumab) is superior to conventional AC-T chemotherapeutic agents for early-stage HER2-positive breast cancer (27).